- Active, not recruiting
NCT04083534: Phase 1/2: First In Human (FIH) Study of REGN5459 in Adult Patients With Relapsed RRMM
Updated: Sep 24, 2022
Anti-BCMA x Anti-CD3 Bispecific Antibody REGN5459
NCT04083534: Phase 1/2: First In Human (FIH) Study of REGN5459 in Adult Patients With Relapsed or Refractory Multiple Myeloma (MM)
First In Human (FIH) Study of REGN5459 in Adult Patients With Relapsed or Refractory Multiple Myeloma (MM)
In the phase 1 portion of the study, the primary objectives are to assess the safety, tolerability, and dose-limiting toxicities (DLTs) and to determine a recommended phase 2 dose regimen (RP2DR) of REGN5459 as monotherapy in patients with relapsed or refractory multiple myeloma (MM) who have exhausted all therapeutic options that are expected to provide meaningful clinical benefit.
In the phase 2 portion of the study, the primary objective is to assess the preliminary anti-tumor activity of REGN5459 as measured by objective response rate (ORR).
Sponsor
Multiple Locations
ClinicalTrials.gov Identifier: NCT04083534
Official Title: Phase 1/2 FIH Study of REGN5459 (Anti-BCMA x Anti-CD3 Bispecific Antibody) in Patients With Relapsed or Refractory Multiple Myeloma
First Posted : September 10, 2019
Click here for details on ClinicalTrials.gov
Drug: REGN5459
Anti-BCMA/Anti-CD3 Bispecific Antibody REGN5459 (Code C165656)
Anti-BCMA x Anti-CD3 Bispecific Antibody REGN5459
Anti-BCMA/Anti-CD3 Bispecific Antibody REGN5459
Anti-BCMA/CD3 Bispecific Antibody REGN5459
Anti-CD3/Anti-BCMA Bispecific Antibody REGN5459
REGN 5459
REGN-5459
REGN5459
Locations
United States, Indiana
United States, Michigan
United States, Minnesota
United States, New York
United States, Texas
United States, Wisconsin
Related Posts
NCT05164250: Compassionate Use (CU) of REGN5458 for Relapsed or Refractory Multiple Myeloma (MM)
NCT05137054: Phase 1: REGN5458 (Anti-BCMA x Anti-CD3 Bispecific Antibody) Plus Other Tx RRMM
NCT03761108: Phase 1/2 - REGN5458 (Anti-BCMA x Anti-CD3 Bispecific Antibody) in Refractory MM